Your browser doesn't support javascript.
loading
HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes.
Wang, Sophia S; Carrington, Mary; Berndt, Sonja I; Slager, Susan L; Bracci, Paige M; Voutsinas, Jenna; Cerhan, James R; Smedby, Karin E; Hjalgrim, Henrik; Vijai, Joseph; Morton, Lindsay M; Vermeulen, Roel; Paltiel, Ora; Vajdic, Claire M; Linet, Martha S; Nieters, Alexandra; de Sanjose, Silvia; Cozen, Wendy; Brown, Elizabeth E; Turner, Jennifer; Spinelli, John J; Zheng, Tongzhang; Birmann, Brenda M; Flowers, Christopher R; Becker, Nikolaus; Holly, Elizabeth A; Kane, Eleanor; Weisenburger, Dennis; Maynadie, Marc; Cocco, Pierluigi; Albanes, Demetrius; Weinstein, Stephanie J; Teras, Lauren R; Diver, W Ryan; Lax, Stephanie J; Travis, Ruth C; Kaaks, Rudolph; Riboli, Elio; Benavente, Yolanda; Brennan, Paul; McKay, James; Delfau-Larue, Marie-Hélène; Link, Brian K; Magnani, Corrado; Ennas, Maria Grazia; Latte, Giancarlo; Feldman, Andrew L; Doo, Nicole Wong; Giles, Graham G; Southey, Melissa C.
Afiliação
  • Wang SS; Department of Population Sciences, Beckman Research Institute and the City of Hope, Duarte, California. sowang@coh.org.
  • Carrington M; Cancer and Inflammation Program, Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland, and Ragon Institute of MGH, MIT, and Harvard, Cambridge, Massachusetts.
  • Berndt SI; Division of Cancer Epidemiology and Genetics, NCI, Bethesda, Maryland.
  • Slager SL; Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota.
  • Bracci PM; Department of Epidemiology and Biostatistics, University of California-San Francisco, San Francisco, California.
  • Voutsinas J; Department of Population Sciences, Beckman Research Institute and the City of Hope, Duarte, California.
  • Cerhan JR; Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota.
  • Smedby KE; Department of Medicine Solna, unit of clinical epidemiology, Karolinska Institutet, Stockholm, Sweden.
  • Hjalgrim H; Hematology Center, Karolinska University Hospital, Stockholm, Sweden.
  • Vijai J; Department of Epidemiology Research, Division of Health Surveillance and Research, Statens Serum Institut, Copenhagen, Denmark.
  • Morton LM; Department of Hematology, Rishospitalet, Copenhagen, Denmark.
  • Vermeulen R; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, New York.
  • Paltiel O; Division of Cancer Epidemiology and Genetics, NCI, Bethesda, Maryland.
  • Vajdic CM; Institute for Risk Assessment Sciences, Utrecht University, Utrecht, the Netherlands.
  • Linet MS; Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands.
  • Nieters A; Braun School of Public Health and Community Medicine, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
  • de Sanjose S; Centre for Big Data Research in Health, The University of New South Wales, Sydney, New South Wales, Australia.
  • Cozen W; Division of Cancer Epidemiology and Genetics, NCI, Bethesda, Maryland.
  • Brown EE; Centre for Chronic Immunodeficiency, University Medical Center Freiburg, Freiburg, Baden-Württemberg, Germany.
  • Turner J; Unit of Infections and Cancer, Cancer Epidemiology Research Programme, Institut Català d' Oncologia, IDIBELL, 08908 L'Hospitalet de Llobregat, Barcelona, Spain.
  • Spinelli JJ; CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
  • Zheng T; Norris Comprehensive Cancer Center, Keck School of Medicine of USC, Departments of Preventive Medicine and Pathology, University of Southern California, Los Angeles, Calfornia.
  • Birmann BM; Department of Pathology, School of Medicine and the UAB Comprehensive Cancer Center, The University of Alabama at Birmingham, Birmingham, Alabama.
  • Flowers CR; Department of Histopathology, Douglass Hanly Moir Pathology, Sydney, Australia.
  • Becker N; Faculty of Medicine and Health Sciences, Macquarie University, Sydney, Australia.
  • Holly EA; Cancer Control Research, British Columbia Cancer Agency, Vancouver, British Columbia, Canada.
  • Kane E; School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada.
  • Weisenburger D; Department of Epidemiology, School of Public Health, Brown University, Providence, Rhode Island.
  • Maynadie M; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
  • Cocco P; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia.
  • Albanes D; Division of Clinical Epidemiology, German Cancer Research Centre, Heidelberg, Baden-Württemberg, Germany.
  • Weinstein SJ; Department of Epidemiology and Biostatistics, University of California-San Francisco, San Francisco, California.
  • Teras LR; Department of Health Sciences, University of York, York, United Kingdom.
  • Diver WR; Department of Pathology, City of Hope, Duarte, California.
  • Lax SJ; Registry of Hematological Malignancies of Cote d'Or, INSERM UMR1231, University of Burgundy and Dijon University Hospital, Dijon, France.
  • Travis RC; Department of Public Health, Clinical and Molecular Medicine, University of Cagliari, Cagliari, Italy.
  • Kaaks R; Division of Cancer Epidemiology and Genetics, NCI, Bethesda, Maryland.
  • Riboli E; Division of Cancer Epidemiology and Genetics, NCI, Bethesda, Maryland.
  • Benavente Y; Epidemiology Research Program, American Cancer Society, Atlanta, Georgia.
  • Brennan P; Epidemiology Research Program, American Cancer Society, Atlanta, Georgia.
  • McKay J; Department of Health Sciences, University of York, York, United Kingdom.
  • Delfau-Larue MH; Cancer Epidemiology Unit, University of Oxford, Oxford, United Kingdom.
  • Link BK; Division of Clinical Epidemiology, German Cancer Research Centre, Heidelberg, Baden-Württemberg, Germany.
  • Magnani C; School of Public Health, Imperial College London, London, United Kingdom.
  • Ennas MG; Unit of Infections and Cancer, Cancer Epidemiology Research Programme, Institut Català d' Oncologia, IDIBELL, 08908 L'Hospitalet de Llobregat, Barcelona, Spain.
  • Latte G; CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
  • Feldman AL; International Agency for Research on Cancer, Lyon, France.
  • Doo NW; Department of Immunology, CHU Henri Mondor, Créteil, France.
  • Giles GG; Department of Immunology, CHU Henri Mondor, Créteil, France.
  • Southey MC; INSERM U 955, CHU Henri Mondor, Créteil, France.
Cancer Res ; 78(14): 4086-4096, 2018 07 15.
Article em En | MEDLINE | ID: mdl-29735552
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfoma não Hodgkin / Antígenos de Histocompatibilidade Classe I / Antígenos de Histocompatibilidade Classe II Tipo de estudo: Etiology_studies / Observational_studies / Risk_factors_studies Limite: Female / Humans / Male Idioma: En Revista: Cancer Res Ano de publicação: 2018 Tipo de documento: Article País de publicação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfoma não Hodgkin / Antígenos de Histocompatibilidade Classe I / Antígenos de Histocompatibilidade Classe II Tipo de estudo: Etiology_studies / Observational_studies / Risk_factors_studies Limite: Female / Humans / Male Idioma: En Revista: Cancer Res Ano de publicação: 2018 Tipo de documento: Article País de publicação: Estados Unidos